Suchergebnisse - "Zhou, Caicun"

PubPharm (648)

1

Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer

enthalten in: Clinical and translational medicine | 2024

von Zhang, X. | Wang, X. | Wen, Y. | +3

2

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

enthalten in: BMC medicine | 2024

von Han, R. | Guo, H. | Shi, J. | +8

3

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

enthalten in: BMC medicine | 2024

von Han, R. | Guo, H. | Shi, J. | +8

4

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Hertz, D. | Joerger, M. | Bang, Y. | +8

5

Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer : a multi-institutional retrospective cohort study

enthalten in: MedComm | 2024

von Wu, L. | Cheng, B. | Sun, X. | +9

6

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Wang, L. | Luo, Y. | Ren, S. | +17

7

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2) : A multicenter, randomized, double-blind, phase 3 trial

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Paz-Ares, L. | Goto, Y. | Wan-Teck Lim, D. | +15

8

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1% : results from a multicenter, open-label, phase 2 trial

enthalten in: Journal for immunotherapy of cancer | 2024

von Ren, S. | Wang, X. | Han, B. | +19

9

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

enthalten in: Cancer cell | 2024

von Zhou, C. | Hu, Y. | Arkania, E. | +24

CommentIn: Cancer Cell. 2024 Feb 12;42(2):172-174. - PMID 38350419

10

VTE with Amivantamab plus Chemotherapy in NSCLC. Reply

enthalten in: The New England journal of medicine | 2024

von Zhou, C. | Agrawal, T. | Girard, N.

CommentOn: N Engl J Med. 2023 Nov 30;389(22):2039-2051. - PMID 37870976

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[65]